Objectives: Plasmacytoid urothelial carcinoma (PUC) of the bladder is a rare histologic variant. We retrospectively analyzed a large series of bladder PUC from a single institution.
Urothelial carcinoma (UC) is the most common malignancy in the urinary bladder, accounting for approximately 90% of all bladder neoplasms. 1 Most UCs are noninvasive papillary lesions at presentation. However, 20% to 30% of UCs invade the bladder wall, and some even metastasize to lymph nodes or other organs. Invasive UC exhibits a remarkable tendency toward divergent differentiation, leading to a variety of histologic variants. 1,2 These UC variants not only have distinct microscopic features but also demonstrate aggressive behaviors associated with poor clinical outcome. Recognizing the UC variants is important for providing optimal care, as patients with these aggressive variants may benefit from novel therapeutic approaches that differ from those used for conventional UC. 3 However, recognizing UC variants, particularly at metastatic sites, may be difficult since the variants' histologic features are not limited to UC but may be associated with other neoplastic diseases. Thus, immunohistochemistry is often employed to aid the differential diagnosis of UC variants. 4, 5 Plasmacytoid UC (PUC) is a rare UC variant, accounting for 1% to 3% of invasive UCs. [6] [7] [8] Unlike conventional UC, PUC is characterized by discohesive cells with eccentrically placed nuclei and abundant cytoplasm, resembling plasma cells. Since PUC was first reported in the bladder two decades ago, 9, 10 there have been limited studies regarding this rare variant disease, and most studies have been based on single-case reports and small cohorts of patients.
the cases were often collected from multiple institutes where patients were likely to undergo varied treatment. [11] [12] [13] Herein we describe the largest case series of PUC from a single institution, providing detailed clinicopathologic and immunohistochemical features of this rare disease.
Materials and Methods

Patients
After the institutional review board at The University of Texas MD Anderson Cancer Center approved the study, we searched our pathology database from 1992 to 2014 and found 49 cases of PUC of the urinary bladder. All 49 patients underwent transurethral biopsy or resection of the tumor, and 39 patients underwent radical cystectomy or cystoprostatectomy. The patients' archived H&E-stained slides were retrieved from our files and reviewed for pathologic analysis, including PUC histologic features, PUC amount, tumor grade, association with UC and other variants, lymphovascular invasion, metastasis to lymph nodes and other organs, and cancer stage. Clinical data, including patients' demographics, treatments, and outcomes, were retrieved from their medical records. The tumors were graded according to the World Health Organization/International Society of Urologic Pathology criteria 1 and staged according to the 2010 American Joint Committee on Cancer TNM criteria. 14 In cases in which cystectomy was not performed, tumor stage was determined based on clinical and radiographic findings.
Immunohistochemistry
Immunohistochemical staining was performed on selected cases using routine sections as well as tissue microarray (TMA) sections. TMA consisted of 1-mm PUC tissue cores (two cores per patient) and was constructed using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD). The following monoclonal antibodies were used for immunostaining: GATA-3 (clone HG3-31, 1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), uroplakin II (clone BC-21, 1:00 dilution; Biocare, Concord, CA), cytokeratin (CK) 7 (clone OV-TL 12/30, 1:100 dilution; Dako, Carpinteria, CA), CK20 (clone Ks20.8, 1:4,000 dilution; Dako), CD138 (clone M115, 1:600 dilution; Dako), CD56 (clone 123C3, 1:100 dilution; Life Technologies, Carlsbad, CA), p63 (clone 4A4, 1:1,000 dilution; Santa Cruz Biotechnology), E-cadherin (clone HECD-1, 1:7,000 dilution; Invitrogen, Carlsbad, CA), retinoblastoma (RB; clone LM95.1, 1:30 dilution; Millipore, San Diego, CA), programmed cell death protein 1 (PD-1; clone MRQ-22, 1:100 dilution; Cell Marque, Rocklin, CA), and programmed death-ligand 1 (PD-L1; clone SP142, 1:100 dilution; Spring Bioscience, Pleasanton, CA). Briefly, 4-lm-thick sections were deparaffinized in xylene and hydrated in graded alcohol. Immunostaining was performed using a BOND-MAX autostainer (Leica Biosystems, Buffalo Grove, IL). Slides were incubated with the primary antibody and then with a visualization reagent (secondary goat anti-mouse immunoglobulin and horseradish peroxidase linked to a dextran polymer backbone). The slides were then rinsed with distilled water, incubated with a 3,3 0 -diaminobenzidine substrate-chromogen solution, and subjected to Mayer hematoxylin counterstaining. The immunohistochemical slides were evaluated by two pathologists (M.D.F. and C.C.G.) blinded to patient identity and reported as either positive or negative.
Statistical Analysis
The overall survivals for patients with PUC at different stages were compared using the Kaplan-Meier method with the Prism 6 software program (GraphPad Software, La Jolla, CA). The Fisher exact test was used to calculate twotailed P values. P values less than .05 were considered statistically significant.
Results
Demographic and Pathologic Findings
The patients consisted of 44 men and five women with a mean age of 62 years (range, 45-86 years) at the time of PUC diagnosis. Gross hematuria was the most common presenting symptom, occurring in 61% of the patients for whom clinical information was available. Other common symptoms included dysuria, urinary frequency, and abdominal pain.
All 49 patients received transurethral biopsy or resection of tumor, and 39 patients received radical cystectomy or cystoprostatectomy. The tumors demonstrated a diffusely infiltrative growth pattern Image 1A . The tumor cells were discohesive with eccentrically placed nuclei and moderate to abundant eosinophilic cytoplasm, closely resembling plasma cells Image 1B . The PUC component accounted for a mean of 68% (range, 5%-100%) of the tumor. PUCs were pure in 23 cases and mixed with other UC types in 26 cases Image 1C , including conventional UC (n ¼ 19), sarcomatoid (n ¼ 5), micropapillary (n ¼ 3), nested (n ¼ 2), and small cell carcinoma (n ¼ 1) variants. Fourteen cases had tumor cells with signet ring morphology Image 1D , and 21 cases showed lymphovascular invasion. The tumors invaded the lamina propria (pT1; n ¼ 4), muscularis propria (pT2; n ¼ 16), perivesical adipose tissue (pT3; n ¼ 17), and adjacent organs (pT4; n ¼ 12). Thirty-two patients underwent lymph node dissection, and 15 (47%) had lymph node metastasis.
Immunohistochemical Analysis
Immunohistochemical stains were performed in selected cases Table 1 , in which the diagnosis was uncertain based on routine H&E examination. Overall, PUCs expressed CK7 (89%; 17/19), CK20 (76%; 13/17), GATA-3 (64%; 14/22), p63 (40%; 4/10), CD56 (33%; 1/3), and CD138 (100%; 2/2). Also, 11 (69%) of 16 PUCs demonstrated cytoplasmic and membranous staining for uroplakin II Image 2A , a specific urothelial marker. Whereas 22 (73%) of 30 PUCs were negative for E-cadherin expression Image 2B , the remaining eight (27%) of 30 exhibited focal E-cadherin expression Image 2C , which was characterized by circumferential membranous staining for E-cadherin. In addition, 20 (63%) of 32 PUCs lacked nuclear staining for RB1 Image 2D , and all were negative for PD-1 and PD-L1.
Treatment and Outcomes
Treatment and follow-up information was available for 44 patients. Twenty-three patients received both chemotherapy and radical cystectomy, 10 patients received chemotherapy only, five patients received radical cystectomy only, four patients received both chemotherapy and radiation treatment, and two patients received radical cystectomy, chemotherapy, and radiation treatment. The average follow-up time was 23 months (range, 4-99 months). Twenty-five patients died of PUC at a mean of 23 months (range, 4-99 months), and 19 patients were alive at a mean of 22 months (range, 6-78 months). Among the patients with follow-up information, one of three patients with pT1 tumors died at 17 months, eight of 14 patients with pT2 tumors died at a mean of 29 months, seven of 15 patients with pT3 tumors died at a mean of 31 months, and seven of 10 patients with pT4 tumors died at a mean of 13 months. Although patients with PUCs at advanced stages had lower overall survival rates than did those with tumors at lower stages Figure 1 , the difference was not significant (P ¼ .11), probably owing to the limited number of patients with pT1 tumors in this cohort. Nonetheless, the median survival time in patients with pT4 PUC was 15 months, which was significantly shorter than that in patients with pT1 to pT3 disease (47 months; P ¼ .008).
Discussion
This retrospective analysis of the largest series of PUC from a single institution has led to important findings that may help understand the clinicopathologic and immunohistochemical features of this rare disease. Our findings support that most PUCs are present at an advanced stage and diffusely invade the bladder wall. We also found that PUCs often coexist with conventional UC and other histologic variants, such as sarcomatoid, micropapillary, nested, and small cell carcinoma. Signet ring morphology is another frequent histologic feature associated with PUC. Our immunohistochemical analysis demonstrated expression of the urothelial markers uroplakin II and GATA-3 in most PUCs, supporting the urothelial origin of PUC. The loss of E-cadherin expression in PUC cells may contribute to the tumor's characteristic discohesion and diffusely infiltrative growth pattern. Most PUCs lack expression of the RB gene, suggesting that the abnormal function of the RB gene plays an important role in the development of PUC. The prognosis for PUC remains poor despite the use of multimodality treatment.
Several previous studies demonstrated that the behavior of PUC is more aggressive than that of conventional UC. [15] [16] [17] Kaimakliotis et al 18 reported that the presence of PUC in a transurethral resection or biopsy specimen was significantly associated with non-organ-confined disease, and the highly aggressive nature of PUC made it less important to differentiate between non-muscle-and muscle-invasive diseases in a biopsy specimen. In radical cystectomy, PUC showed a high rate of extravesical spread, particularly involving the peritoneal lining. Ricardo-Gonzalez et al 19 found that 33% of patients with PUC had intraperitoneal disease spread and 20% had subsequent metastasis involving serosal surfaces. In comparison with conventional UC, PUC has a higher rate of lymph node metastasis and is more likely to have positive surgical margins after radical cystectomy. 18 Furthermore, overall and disease-specific survival in PUC patients were worse than those in patients with conventional UC. 15, 18 In the present study, 59% of PUCs invaded through the bladder wall and 27% involved the peritoneum or other adjacent organs. In addition, 43% of patients who underwent lymph node dissections had metastatic disease. Despite the use of multimodality treatment, 57% of patients survived for only a short time (mean, 23 months). Our findings support that PUC is a highly malignant disease that may warrant more aggressive therapy than that for conventional UC. Our study also demonstrated loss of membranous staining for E-cadherin in most PUC cases. E-cadherin is a cell adhesion molecule that interacts with the actin cytoskeleton by binding with a-, b-, and c-catenin. 20 Loss of E-cadherinmediated cell adhesion is thought to account for the characteristic discohesion of PUC, leading to its single-cell growth pattern and aggressive clinical behavior. 13, [21] [22] [23] Recently,
Al-Ahmadie et al 24 found that PUC frequently had truncating somatic mutations of cadherin 1 (CDH1), the gene encoding for E-cadherin, whereas there were no CDH1-truncating mutations in conventional UCs in the Cancer Genome Atlas database. 25 Interestingly, previous studies demonstrated that other carcinomas with morphologic features similar to PUC, such as lobular breast carcinoma and diffused gastric carcinoma, also had decreased expression of E-cadherin owing to frequent CDH1 mutations. [26] [27] [28] Furthermore, an in vitro study demonstrated that suppression of the CDH1 gene resulted in increased migration of the transformed cells, suggesting that E-cadherin plays an important role in tumor invasion. 24 In the present study, we found that although most PUC cases had complete loss of Ecadherin, a small subset showed robust membranous staining for E-cadherin. Similarly, Keck et al 13 also found that some PUCs exhibited strong membranous staining for Ecadherin. Although loss of E-cadherin-mediated cell adhesion is thought to account for the characteristic discohesion and infiltrative growth pattern of PUC, some PUCs may have alterations of b-catenin, which may also contribute to its discohesive and infiltrative nature.
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Image 2 Immunohistochemical features of plasmacytoid urothelial carcinoma (PUC). A, PUC shows cytoplasmic and membranous staining for uroplakin II (Â200). B, PUC lacks E-cadherin expression, whereas the adjacent normal urothelium exhibits circumferential membranous staining for E-cadherin (Â200). C, PUC occasionally shows circumferential membranous staining for E-cadherin (Â200). D, PUC lacks nuclear staining for retinoblastoma 1 (RB1), whereas the adjacent normal urothelium exhibits nuclear staining for RB1 (Â200).
Several immunohistochemical markers have been used to predict the response of bladder UC to novel targeted therapy drugs. [29] [30] [31] The RB gene encodes for a tumor suppressor protein that regulates cell cycle regulation, senescence, and cell apoptosis. 32 Investigators have found RB mutations in 21% of non-muscle-invasive UCs and 36% of muscleinvasive UCs, suggesting that RB mutations are associated with an invasive disease. 33, 34 A recent study demonstrated that patients with bladder UC lacking RB expression may benefit from forced expression of the RB protein using tumor-targeted liposomal delivery method. 35 In the present study, we found that 62% of patients with PUC lacked RB expression on immunohistochemical analysis, suggesting that abnormal function of the RB gene underlies the aggressive behavior of PUC and that PUC may be a suitable candidate for the RB-targeted therapy. PD-L1 plays a major role in suppressing the immune system by forming a complex with PD-1. 36 Upregulation of PD-L1 expression and subsequent formation of the PD-L1 complex may enable certain cancers to evade the host immune system. 37 Monoclonal antibodies targeting PD-L1 boost the immune system and have measurable success against advanced bladder UC with relatively few side effects. 38, 39 However, no PUC cases in the present study had expression of PD-L1 or PD-1, suggesting that PUC may not be a suitable candidate for the PD-L1-targeted immunotherapy. Plasmacytoid morphology is not unique to UC and can be found in a number of other neoplasms in the urinary bladder, including plasmacytoma, lymphoma, melanoma, paraganglioma, and rhabdomyosarcoma. Furthermore, carcinomas that metastasize from the breast, stomach, and other organs may involve the bladder and show plasmacytoid morphology. 40 It is important to differentiate PUC from other plasmacytoid neoplasms in the bladder because they have quite different prognoses and therapeutic implications. However, it may be challenging to distinguish between PUC and other bladder plasmacytoid neoplasms, especially on limited biopsy specimens. In general, the presence of conventional UC, including UC in situ, would support a diagnosis of PUC. In difficult cases, a panel of immunohistochemical stains can help the differential diagnosis. [11] [12] [13] In the present study, we found that most PUCs exhibited positive immunoreactivity with CK7 and CK20. Thus, along with other cytokeratins, CK7 and CK20 can be used to differentiate lymphoma, plasmacytoma, melanoma, paraganglioma, and rhabdomyosarcoma. Furthermore, we demonstrated that most PUCs expressed GATA-3 and uroplakin II, which can be used to differentiate PUC from metastatic plasmacytoid carcinomas from other organs. In addition, non-UC plasmacytoid neoplasms express their own characteristic immunohistochemical markers, which also can be used for the differential diagnosis. Figure 1 Overall survival of patients with plasmacytoid urothelial carcinoma at different pathologic stages.
